Journal of Oncology / 2010 / Article / Tab 5 / Research Article
Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study Table 5 Characteristics of patients receiving Gefitinib.
Somatic Mutational Spectrum EGFR No Age Previous Chemo-therapy Response TTP Survival RAS EGFR Exons 18–21 BRAF exon 15 MET
5
-
3
exon 14 intro-exon boundaries Her2 FISH IHC 1 38 Y PD 1.25 8.85 WT WT WT WT Y781C ND 0 2 50 Y PR 2.20 5.70 WT WT WT WT WT ND ND 3 75 Y SD 5.31 6.46 WT WT WT WT WT WT 0 4 59 Y NE 2.66 2.66 WT WT WT WT Q795R WT 3 W825X 5 63 Y SD 12.13 12.13 WT delL747-P753insS WT WT WT Amp ND 6 66 Y PD 2.07 2.43 WT WT WT WT WT WT 3 7 63 Y SD 7.74 9.54 WT delL747-P753insS WT WT WT WT 0 8 72 Y SD 8.46 11.70 WT R836R WT WT WT Amp 3 V843I 9 62 Y SD 7.84 8.03 WT WT WT WT WT ND 3 10 72 Y PR 3.11 3.11 WT WT WT WT WT WT 3 11 75 Y PD 5.15 5.15 WT WT WT WT WT Amp 2 12 66 N PR 4.10 11.64 WT WT WT WT WT Gain 2 13 74 N PD 3.57 9.15 WT WT WT WT WT WT 3 14 61 N PD 1.64 3.74 WT WT WT WT WT WT 3 15 70 N CR 15.05 17.57 G12D WT WT WT WT WT 3 16 69 Y PD 0.82 10.75 WT WT WT WT WT WT 0 17 63 Y PD 0.75 2.89 WT WT WT WT WT WT 3 18 72 Y NE 4.59 4.59 WT WT WT WT WT WT 3 19 59 Y SD 1.48 3.80 WT WT WT WT WT WT 2
Abbreviations: Y: Yes; N: No; IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; ND: not determined; gain: aneuploidy; CR: complete response; PR: partial response; SD: stable disease; PR: progressive disease; NE: not evaluable.
